© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
August 03, 2022
The researchers combined machine learning and rule-based natural language processing to develop an algorithm that leveraged electronic health records to identify patients with nmCRPC.
April 12, 2022
Initial data from the phase 1/2a modular PETRA trial showed that the next-generation highly selective PARP1 inhibitor AZD5305 had comparable safety and promising clinical activity compared with first-generation PARP inhibitors.
February 22, 2022
September 18, 2021
The dual immunotherapy regimen maintained a survival benefit over single-agent sunitinib in patients with advanced renal cell carcinoma.